Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming ...

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...

As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...

Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

On Wednesday, the U.S. Food and Drug Administration took the unusual step of authorizing pharmacists to directly prescribe antiviral medication Paxlovid to patients testing positive for COVID-19.

Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, said in a letter last week that the demand for Zepbound and Mounjaro is being met, negating the need for ...

The US Food and Drugs Administration (FDA) has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald ...